Five Prime Therapeutics Inc (FPRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Five Prime Therapeutics Inc (FPRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH136045D
  • |
  • Pages: 61
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Five Prime Therapeutics Inc (Five Prime) is a biotechnology company that focuses on discovery and development of protein therapeutics. The company offer wide range of products for cancer, inflammatory disorders, muscle disease and other conditions. Five Prime develops proprietary protein screening technologies and rapid in vivo protein production system to identify new targets for protein therapeutics. It also offer protein library that contains full-length, biologically active and structurally complete proteins. The company works in partnership with international pharmaceutical companies that include Bristol-Myers Squibb, UCB Pharma and GlaxoSmithKline among others. Five Prime is headquartered in South San Francisco, California, the US.

Five Prime Therapeutics Inc (FPRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Five Prime Therapeutics Raises US$10 Million In Venture Financing 12

Partnerships 12

Five Prime Therapeutics Enters into Agreement with University of Minnesota Medical School 12

Vaccinex Enters into Drug Discovery Agreement with Five Prime Therapeutics 13

Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 14

Five Prime Therapeutics Enters Into Research Agreement With Adimab 16

UCB Enters Into Research Agreement With Five Prime Therapeutics 16

Five Prime Therapeutics Enters Into Co-Development Agreement With GlaxoSmithKline 18

GlaxoSmithKline Expands Co-Development Agreement With Five Prime Therapeutics 19

Dyax Enters Into Research Agreement With Five Prime Therapeutics 19

Licensing Agreements 20

Five Prime Therapeutics Expand Licensing Agreement with Bristol-Myers Squibb 20

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 21

Bristol-Myers Squibb Enters into Licensing Agreement with Five Prime Therapeutics 22

Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 24

Five Prime Therapeutics Enters into Licensing Agreement with Inhibrx 25

Bluebird bio Enters into Licensing Agreement with Five Prime Therapeutics 26

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 27

ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 28

Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 29

Five Prime Therapeutics Amends its Licensing Agreement with Galaxy Biotech 30

Human Genome Sciences Enters Into Licensing Agreement With FivePrime Therapeutics For FP-1039 32

Equity Offering 33

Five Prime Therapeutics Raises USD84.3 Million in Public Offering of Shares 33

Five Prime Therapeutics Completes Private Placement Of Shares For US$21 Million 35

Five Prime Therapeutics Completes Public Offering Of Shares For US$43 Million 35

Five Prime Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option Of IPO For US$71.8 Million 37

Five Prime Therapeutics Inc-Key Competitors 39

Key Employees 40

Locations And Subsidiaries 41

Head Office 41

Recent Developments 42

Financial Announcements 42

Feb 23, 2017: Five Prime Announces Fourth Quarter and Full Year 2016 Financial Results 42

Nov 03, 2016: Five Prime Announces Third Quarter 2016 Results and Provides Business Update 45

Aug 04, 2016: Five Prime Announces Second Quarter 2016 Results and Provides Business Update 47

May 05, 2016: Five Prime Announces First Quarter 2016 Results and Provides Business Update 49

Mar 10, 2016: Five Prime Announces Fourth Quarter and Full Year 2015 Financial Results 51

Corporate Communications 53

Mar 20, 2017: Five Prime Therapeutics Announces Executive Changes 53

Sep 20, 2016: Five Prime Therapeutics Announces Key Executive Promotions 54

Jun 01, 2016: Five Prime Therapeutics Appoints Dr. Robert Sikorski as Chief Medical Officer 55

Mar 16, 2016: Five Prime Therapeutics Announces Changes to Board of Directors 56

Jan 05, 2016: Five Prime Therapeutics Appoints Prominent Immuno-Oncology Thought Leaders to Scientific Advisory Board 57

Product Approvals 58

Jan 13, 2016: Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA008 in Pigmented Villonodular Synovitis 58

Clinical Trials 59

Nov 11, 2016: Five Prime to Present Preclinical Data at 2016 SITC Annual Meeting Demonstrating Potent Anti-Tumor Activity with Novel Tetravalent Anti-GITR Antibody 59

Nov 03, 2016: Five Prime to Present Preclinical Data at 2016 SITC Annual Meeting For Novel Tetravalent Anti-GITR Antibody 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61

List of Figures

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Five Prime Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Five Prime Therapeutics Raises US$10 Million In Venture Financing 12

Five Prime Therapeutics Enters into Agreement with University of Minnesota Medical School 12

Vaccinex Enters into Drug Discovery Agreement with Five Prime Therapeutics 13

Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 14

Five Prime Therapeutics Enters Into Research Agreement With Adimab 16

UCB Enters Into Research Agreement With Five Prime Therapeutics 16

Five Prime Therapeutics Enters Into Co-Development Agreement With GlaxoSmithKline 18

GlaxoSmithKline Expands Co-Development Agreement With Five Prime Therapeutics 19

Dyax Enters Into Research Agreement With Five Prime Therapeutics 19

Five Prime Therapeutics Expand Licensing Agreement with Bristol-Myers Squibb 20

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 21

Bristol-Myers Squibb Enters into Licensing Agreement with Five Prime Therapeutics 22

Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 24

Five Prime Therapeutics Enters into Licensing Agreement with Inhibrx 25

Bluebird bio Enters into Licensing Agreement with Five Prime Therapeutics 26

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 27

ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 28

Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 29

Five Prime Therapeutics Amends its Licensing Agreement with Galaxy Biotech 30

Human Genome Sciences Enters Into Licensing Agreement With FivePrime Therapeutics For FP-1039 32

Five Prime Therapeutics Raises USD84.3 Million in Public Offering of Shares 33

Five Prime Therapeutics Completes Private Placement Of Shares For US$21 Million 35

Five Prime Therapeutics Completes Public Offering Of Shares For US$43 Million 35

Five Prime Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option Of IPO For US$71.8 Million 37

Five Prime Therapeutics Inc, Key Competitors 39

Five Prime Therapeutics Inc, Key Employees 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Five Prime Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16143
Site License
USD 500 INR 32285
Corporate User License
USD 750 INR 48428

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com